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The large scale introduction of soft-tissue imaging (e.g. via 
computed tomography) and the multiyear experience in its 
use paved the way, at least in radiotherapy with photons, for 
the development of adaptive treatments, where image 
datasets acquired during the treatment cycle are used to 
evaluate and tune the dose distributions actually delivered to 
the patient. 
In proton therapy the presence of range uncertainties, and 
their effect in terms of dose perturbations, has been tackled 
so far mostly looking at source of range and dose 
uncertainties other than anatomy deformation, e.g. range 
error due to imperfections in the CT scan calibration and 
setup errors. However, neither improved CT calibration nor 
the use of sophisticated planning approaches such as robust 
optimization are coping with dose perturbations due to 
anatomy changes. As a consequence, proton therapy has for 
quite some time approached the issue in a defensive way, 
i.e. focusing on dose indications where anatomy changes are 
not expected (e.g. the skull) or at least choosing beam 
directions going through regions of the body where such 
changes are less likely. 
The broadening of the indications considered to be suitable 
for proton therapy and the increased availability of soft 
tissue image guidance in proton therapy treatment rooms is 
slowly allowing for more proactive approaches, where repeat 
CT scans are actually used to modify the treatment 
parameters. 
Starting from clinical cases, we'll see how adaptive therapy 
with protons has some peculiarities with respect to adaptive 
with photons, such as: 
- A more prominent impact of anatomy deformation on the 
dose distribution. The finite range of protons makes the dose 
distribution sensitive even to anatomy variations that would 
not be of concern in photons 
- Adaptive proton therapy needs to rely on high quality 
imaging for dose recalculation and optimization. Since CT 
calibration is an issue even with diagnostic quality CT, any 
further deterioration of the image quality will in principle 
impact the accuracy in dose distribution, thus potentially 
making the treatment adaptation less relevant. 
- Given the strict correlation between anatomy and dose 
distribution, it remains to be seen whether approaches that 
are successful in photons (e.g. the use of plan libraries) are 
safe and effective with protons too. 
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Daily volumetric imaging is essential in adaptive radiation 
therapy (ART) due to patient related uncertainties which may 
occur during the course of radiation treatment. The in room 
Cone-Beam CT (CBCT) imaging has been considered a viable 
option for photon ART, while CBCT just recently emerged in 
proton therapy. CBCT deployment in proton therapy has been 
slow due to technical challenges for design and 
implementation, lower image quality and more importantly 
less HU accuracy relative to CT imaging due to scattered x-
rays. Therefore, the clinical deployment of CBCT in proton 
therapy is still in an early phase and currently is limited to 
treatment setup and detection of potential changes in 
patient anatomy generated by tissue deformation, weight 
loss, physiological changes and tumor shrinkage. The HU 
accuracy of CBCT is more critical in adaptive proton therapy 
(APT) relative to photon ART, as even small differences in HU 
could cause significant range and absolute dose errors. As a 
result, the integrity of the proton dose calculation may be 
easily compromised. Studies showed that photon dose 
calculation discrepancy caused by CBCT HU error can be over 
10% for raw CBCT image data sets and be within 1% for 
scatter corrected CBCT. However, no study up to date has 
demonstrated the feasibility of proton clinical dose 
calculation or treatment planning on raw CBCT data sets and 
therefore currently the primary role of CBCT in APT is to 
trigger the need for CT rescanning for dose adaptation. 
However, there are two major approaches explored to 
overcome current CBCT image data sets limitations. The first 
one employs deformable image registration of the treatment 
planning CT to the daily verification raw CBCT to generate a 
CBCT based stopping power distribution. This method has 
been explored mostly for head and neck dose adaptation. 
The second one aims to improve the raw CBCT data accuracy 
via scatter corrections and in its current stage explored the 
feasibility of raw CBCT based planning on an 
anthropomorphic phantom. As these methodologies are 
developing and new ones emerge, CBCT imaging may further 
evolve and holds the potential to become a viable tool for 
APT. 
 
SP-0501  
Adaptive practice and techniques in proton therapy of the 
lung 
P.C. Park
1The University of Texas MD Anderson Cancer Center, 
Department of Radiation Physics, Houston, USA 
1, H. Li1, L. Dong2, J. Chang3, X. Zhu1 
2Scripps Proton Therapy Center, Radiation Oncology, San 
Diego, USA 
3The University of Texas MD Anderson Cancer Center, 
Department of Radiation Oncology, Houston, USA 
 
Adaptive radiation therapy is the practice of modifying initial 
treatment plan in order to accommodate the changes in a 
patient’s anatomy, organ motion, and biological changes 
during course of treatment. Within this scope of definition, it 
can be further classified based on different time scale going 
from offline (between fractions) to online (prior to a 
fraction), and to real time (during fraction) modification in 
beam delivery. The dose distribution of proton is “non-static” 
relative to the change in patient anatomy because the finite 
path length of protons is tissue density dependent. Therefore 
the adaptive radiation therapy is more relevant for proton 
than photon. For the same reason, for moving target in 
particular, online or real time adaptation may become more 
important for proton therapy. During initial treatment 
planning phase, proton ranges in patient must be determined 
precisely in order to take the advantage of Bragg peak. 
Changes in water equivalent thickness along the beam path 
due to breathing motion must be accounted by robust 
planning strategies. Any significant changes in proton range 
from what was calculated should be detected and prompt for 
an adaptive re-plan. Treatment sites that are likely to change 
in anatomy during the course of treatment or during 
treatment are particularly important. In this regard, lung 
cancer is one of the most relevant sites to practice adaptive 
proton therapy. Over 40% of lung tumors move more than 5 
mm and 10% moves greater than 10 mm [1] with possibility of 
changes in breathing pattern during the course of treatment. 
The change in tumor shape or density and decrease in tumor 
volume as tumors respond to the radiation also raise another 
challenge for proton therapy. The protons can travel further 
without the tumor tissues to stop them in lung. Previous 
studies found that on average from 0.6 to 2.4% of tumor 
volume can be reduced per day [2]. Adaptive radiation 
therapy requires modification in treatment plan through 
changing contours of targets or organs at risk and beam 
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parameters accordingly and any quality assurance checks that 
are deemed necessary. Therefore the adaptive radiation 
therapy requires more resources when compare to the 
conventional image-guided radiation therapy. In fact, image-
guidance can be considered the first step in adaptive practice 
as it triggers the initial decision to adapt and provide the 3D 
volumetric images that are necessary for adaptive re-plan. 
There have been efforts to create techniques and 
technologies that can facilitate the adaptive planning. In this 
presentation, we will first discuss the state of art practice of 
adaptive proton therapy including the experience at our 
institution. We will review studies assessing the magnitude of 
intra- and inter-fractional changes and its impact on 
delivered proton dose distribution with and without adaptive 
practice. Secondly, we will present the cutting edge ideas 
and techniques that are developed specifically for adaptive 
proton lung therapy in the most recent literature.  
[1] Liu HH, Balter P, Tutt T, et al. Assessing respiration-
induced tumor motion and internal target volume using 4DCT 
for radiation therapy of lung cancer. Int J Radiat Oncol Biol 
Phys 2007;68:531-540  
[2] Sonke JJ, Belderbos J. Adaptive Radiotherapy for lung 
cancer. Semin Radiat Oncol 2010 Apr; 20(2):94-106. 
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The finite range of protons is a two-edged sword. On one 
side, it is the raison d’etre of proton therapy, on the other, a 
potential source of uncertainties in-vivo. As such, both in-
vivo range estimates and adaptive therapy are being 
proposed and pursued for mitigating such uncertainties. 
However, sources of in-vivo range uncertainties are many, 
ranging from systematic uncertainties in the calibration of CT 
Hounsfield units to proton stopping power and inaccuracies in 
dose calculations (for convenience defined here as type I 
uncertainties) to variations in patient positioning and 
anatomy changes during the course of treatment (type 2). 
Whereas, for good quality CT data, type 1 uncertainties can 
result in range uncertainties of a few percent or millimeters 
(about 3% or 6mm in the worst case,) type 2 can result in 
range changes of the order of centimeters. In addition, type 
1 uncertainties will, to a good approximation, be similar 
across all patients of a particular indication and will remain 
the same throughout the duration of a patient’s treatment. 
Type 2 on the other hand will be patient and (potentially) 
treatment day dependent. So, what are the roles of in-vivo 
range measurement and adaptive therapy for dealing with 
these? It seems to this author that in-vivo range verification 
perhaps has a role to play in reducing type 1 uncertainties, 
whereas the best approach to type 2 has to be adaptive 
therapy. Adaptive therapy (based on regular, if not daily, 
imaging) must be pro-active (i.e. the treatment should 
ideally be adapted before delivery), whereas in-vivo range 
verification can only be (at best) reactive (e.g. may be able 
to provide a reason to interrupt a delivery if an error is 
detected). As such, the best use of in-vivo range estimation 
seems to be as part of a population based (commissioning) 
approach in order to verify that CT calibration and dose 
calculations are more and more precise, such that type 1 
uncertainties resulting from pre-treatment imaging 
(necessary to mitigate type 2 errors) can then be reduced as 
much as possible. Such an approach however puts stringent 
demands on the accuracy and precision of in-vivo range 
estimates, with in-vivo resolutions in the millimeter range 
being required in order to significantly improve these 
uncertainties. Will this ever be achievable?  
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One of the most exciting areas of basic, translational and 
clinical research in radiation oncology today is radiotherapy 
with particles, i.e. with protons or heavier ions. The main 
advantage of radiotherapy with protons compared to state-
of-the-art radiotherapy with photons is a decrease of the 
volume of normal tissues irradiated to intermediate and low 
doses, while irradiation of normal tissues to high doses or the 
conformality of the dose to the tumor are usually similar for 
protons and photons. Exceptions include situations where 
critical normal tissues can be excluded by proton therapy 
from the irradiated volume completely or to a large extent. 
The most relevant clinical research question is therefore to 
investigate whether sparing of normal tissue by proton 
therapy leads to clinical relevant benefits which balance the 
higher costs of this treatment. After demonstration of 
relevant sparing of normal tissues, further clinical studies on 
utilizing dose intensification strategies may become another 
important research avenue in those tumors where local or 
locoregional tumor control today are unsatisfactory. 
At present only few centers (often with different 
technologies and patient populations) are active in clinical 
research using protons, which makes fresh thinking on study 
design in radiation oncology necessary, as large scale 
randomized trials will not be feasible in many situations. 
Model-based approaches are a major component of the trial 
methodological portfolio, but alternatives (including 
multicenter stepwise randomized trials, pseudo-randomized 
trials and prospective matched pair trials) may be superior in 
different clinical situations. All of these approaches 
necessitate dedicated clinical research infrastructures and 
complex high-level network formation to reach the power for 
meaningful clinical trials. This also plays an important role in 
terms of radiotherapy stratified by biological parameters, 
which is anticipated to become a clinical reality in the near 
future for several tumor entities. 
Proton (or other particle) therapy holds particular promise to 
further advance personalized radiation oncology. However 
obstacles in trial design, data sampling and integration, or 
analysis may dilute the effects to such an extent that it may 
not be possible to demonstrate it according to generally 
accepted scientific standards. This would be a major hurdle 
for further implementation and reimbursement of this 
auspicious technology, and also for sound medical 
stratification of access of patients in need for this therapy. 
The lecture will discuss opportunities and problems of proton 
therapy in the context of high precision personalized as well 
as biologically stratified radiation oncology, thereby also 
touching trial design, technology development and the 
importance of network formation on a European level. 
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Small animal image guided irradiation platforms are 
revolutionizing the field of preclinical radiobiology by 
facilitating the delivery of clinically relevant irradiation 
